SCHEMBL832148

SCHEMBL832148

CCc1nc(-c2cc(F)cc(F)c2)cc(CC(C)C)c1C(=O)OC

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TRPV3 Q8NET8 1/20 0.36
GCGR P47871 1/20 0.35
CNR2 P34972 1/20 0.33
ADORA3 P0DMS8 3/20 0.33
DHODH Q02127 1/20 0.33
LMNA P02545 1/20 0.32
ALDH1A1 P00352 2/20 0.31
PLA2G2A P14555 2/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
NPC1 O15118 1/20 0.31
CASP3 P42574 1/20 0.31
RAB9A P51151 1/20 0.31
SENP8 Q96LD8 1/20 0.31
SENP7 Q9BQF6 1/20 0.31
SENP6 Q9GZR1 1/20 0.31
BDKRB1 P46663 3/20 0.31
ADORA2A P29274 1/20 0.31
CDK4 P11802 1/20 0.31
CCND1 P24385 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL831717 0.89 CNR2 (0.41) TRPV3GCGRCNR2ADORA3DHODH
SCHEMBL829550 0.87 DHODH (0.36) TRPV3DHODHLMNASMN1; SMN2NPC1
SCHEMBL830487 0.86 SLC6A3 (0.39) TRPV3GCGRDHODHBDKRB1POLB
SCHEMBL830293 0.84 ADORA3 (0.41) ADORA3ALDH1A1SMN1; SMN2RAB9AKMT2A
SCHEMBL831416 0.83 MAPT (0.43) CNR2ADORA3LMNAALDH1A1PLA2G2A
SCHEMBL831040 0.78 LMNA (0.36) CNR2ADORA3LMNAALDH1A1SMN1; SMN2
SCHEMBL831580 0.78 ALDH1A1 (0.51) ADORA3LMNAALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL833067 0.76 CNR2 (0.43) TRPV3CNR2ADORA3DHODHSMN1; SMN2
SCHEMBL830411 0.74 DPP4 (0.41) TRPV3DHODHLMNAALDH1A1L3MBTL1
SCHEMBL831887 0.74 ALDH1A1 (0.47) LMNAALDH1A1L3MBTL1SMN1; SMN2NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-8143411-B2 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2012-03-27 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use BAYER ANIMAL HEALTH GMBH (DE) 2010-09-16 US disclosed
WO-2009033561-A1 SUBSTITUTED 6-PHEYLNICOTINIC ACIDS AND THE USE THEREOF BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100234432-A1 Substituted 6-phenylnicotinic acids and their use SLC5A6, FABP3, NAPRT TRPV3 4035/4885GCGR 3478/4885CNR2 4623/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.